April 16, 2026
NOTES TO EDITORSAbout KhondrionKhondrion is a late-stage clinical biopharmaceutical company focused …
MitoAction in the News
Navigating the FDA’s Complete Response Letter and identifying a path forwardfor SL1009 (DCA).
March 31, 2026
Dear Members of the PDCD Community,
We are deeply grateful for your support and advocacy throughout …
FDA Approval of KYGEVVI Marks a Defining Moment for Mitochondrial Disease Community and Families Affected by TK2d
FOR IMMEDIATE RELEASE
Contact:Emily GrandahlMarketing Coordinator, MitoActionemily@mitoaction.org(888) …
Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease
Originally Published by Tisento Therapeutics on November 3, 2025.
Findings Demonstrate the Importance of Addressing …
Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome
“The approval of FORZINITY, the first treatment option for Barth syndrome and the first approved mitochondria-targeted …
- 1
- 2
- 3
- …
- 28
- Next Page »
